In addition, both mutCREBBP and mutEP300 contribute to lymphomagenesis by enabling unopposed suppression of enhancers by BCL6/SMRT/HDAC3 complexes, suggesting HDAC3-targeted therapy as a precision approach for CREBBP-mutant lymphomas [48], and recent results with specific HDAC3 inhibitors have demonstrated the reactivation of immune responses [49]. This evidence concerns the gene HDAC3 and lymphoma.